Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 465,620 shares of the biopharmaceutical company’s stock after buying an additional 8,093 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Agios Pharmaceuticals were worth $20,687,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AGIO. Farallon Capital Management LLC increased its holdings in Agios Pharmaceuticals by 1.1% in the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after acquiring an additional 63,900 shares in the last quarter. Marshall Wace LLP raised its position in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after purchasing an additional 348,808 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in Agios Pharmaceuticals by 87.3% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock valued at $29,245,000 after buying an additional 316,100 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $13,922,000.

Agios Pharmaceuticals Trading Up 4.5 %

Agios Pharmaceuticals stock opened at $61.64 on Friday. The stock has a market cap of $3.52 billion, a P/E ratio of 5.43 and a beta of 0.80. The company has a 50-day moving average price of $49.93 and a 200 day moving average price of $46.28. Agios Pharmaceuticals, Inc. has a 12-month low of $20.96 and a 12-month high of $62.58.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AGIO. Scotiabank increased their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $52.33.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.